Exicon Co., Ltd. — Delisting Announcement 2016

Jul 13, 2016

Copenhagen, 2016-07-13 13:07 CEST (GLOBE NEWSWIRE) -- As previously disclosed
in company announcement of 11 July 2016, QIAGEN N.V. has initiated a compulsory
redemption of the minority shareholders in Exiqon A/S in accordance with
sections 70 and 72 of the Danish Companies Act. Based on this, the board of
directors of Exiqon A/S decided to request Nasdaq Copenhagen A/S for a
delisting and cancellation from trading of all shares in Exiqon A/S, whereby
the last day of trading would be 3 August 2016. Nasdaq Copenhagen A/S has today
accepted such a request.

Consequently, the last day of trading for the Exiqon shares will be 3 August
2016.

Additional information

Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)

About Exiqon

At Exiqon, we advance the research of when and where genes are expressed. We
empower scientists across the world with best-in-class products and
user-friendly business solutions designed to transform workflows in our
industry. Exiqon operates in two business areas: Exiqon Life Sciences is a
leading provider of flexible solutions for gene expression analysis. Academia,
biotech and pharmaceutical companies around the world use Exiqon’s research
products to make ground-breaking discoveries. Exiqon Diagnostics collaborates
with diagnostic and pharmaceutical companies to develop novel molecular
diagnostic tests for early detection of diseases, which can help physicians
make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For
more information about us, please visit www.exiqon.com